CliffBio
small molecule

EMFLAZA

DEFLAZACORT

Loss of exclusivityJune 2026FDA regulatory exclusivity expiry
CompanyPTC Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameEMFLAZA
Active ingredientDEFLAZACORT
Strength22.75MG/ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2017
Marketing statusRX

Regulatory exclusivity

CodeExpires
ODE-252June 2026

More from PTC Therapeutics

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

EMFLAZA patent cliff — loss of exclusivity June 2026 | CliffBio